These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022
Many years ago, it was decided that the definition of a "small cap" should be a company with a valuation under $2 billion. These days, with some mega caps having risen past the $2 trillion mark, we probably should move that benchmark a little. In this roundtable, three Fool contributors were asked to focus on healthcare companies with market caps under $10 billion, and pick out ones that they expect can deliver $1 billion in sales in 2022.
They nominated Vir Biotechnology (NASDAQ: VIR), Clover Health (NASDAQ: CLOV), and Penumbra (NYSE: PEN) -- a trio of still relatively small companies that have huge potential upsides.
Image source: Getty Images.
Source Fool.com
